GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Huapont Life Sciences Co 002004.SZ · CNY

Materials · Shenzhen · 🇨🇳 China

Compare

4.63

-1.49%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥11.51bn

FY2016FY2025

Net income

CN¥713.2m

FY2016FY2025

Free cash flow

CN¥1.46bn

FY2016FY2025

Shareholders' equity

CN¥10.22bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥11.51bnCN¥11.66bnCN¥11.59bnCN¥13.23bnCN¥12.43bnCN¥10.88bnCN¥10.09bnCN¥10.57bnCN¥9.18bnCN¥7.09bn
Gross profitCN¥4.25bnCN¥3.84bnCN¥4.39bnCN¥5.26bnCN¥4.67bnCN¥4.41bnCN¥4.64bnCN¥4.23bnCN¥2.89bnCN¥2.29bn
Research and developmentCN¥341.6mCN¥375.3mCN¥419.1mCN¥385.2mCN¥329.5mCN¥324.4mCN¥288.0mCN¥349.5mCN¥244.5mCN¥228.0m
Operating incomeCN¥1.51bnCN¥209.0mCN¥926.5mCN¥1.64bnCN¥1.33bnCN¥1.19bnCN¥1.16bnCN¥1.09bnCN¥706.2mCN¥957.4m
Net incomeCN¥713.2m−CN¥299.0mCN¥302.1mCN¥433.5mCN¥667.8mCN¥651.7mCN¥620.2mCN¥506.4mCN¥505.8mCN¥566.9m
Diluted earnings per share0.36-0.150.150.220.340.330.290.250.240.29

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥29.03bnCN¥29.45bnCN¥30.73bnCN¥30.02bnCN¥30.04bnCN¥28.23bnCN¥26.64bnCN¥26.55bnCN¥29.09bnCN¥24.23bn
Cash and short-term investments—CN¥3.94bnCN¥5.61bnCN¥4.89bnCN¥5.42bnCN¥4.98bnCN¥4.05bnCN¥4.35bnCN¥7.71bnCN¥6.03bn
Total liabilitiesCN¥12.05bnCN¥13.98bnCN¥14.14bnCN¥13.47bnCN¥14.22bnCN¥14.09bnCN¥13.39bnCN¥13.80bnCN¥15.79bnCN¥13.52bn
DebtCN¥2.28bnCN¥6.56bnCN¥8.63bnCN¥8.05bnCN¥8.57bnCN¥9.13bnCN¥8.92bnCN¥9.72bnCN¥11.50bnCN¥8.98bn
Shareholders' equityCN¥10.22bnCN¥9.34bnCN¥10.11bnCN¥10.19bnCN¥10.11bnCN¥9.63bnCN¥9.34bnCN¥9.06bnCN¥9.49bnCN¥9.65bn
Shares outstanding1,973m1,973m1,979m1,981m1,979m1,970m2,153m2,004m2,097m1,981m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.10bnCN¥1.63bnCN¥1.59bnCN¥2.41bnCN¥1.27bnCN¥2.37bnCN¥2.08bnCN¥1.91bnCN¥591.4mCN¥511.9m
Capital spending−CN¥638.3m−CN¥956.3m−CN¥1.28bn−CN¥1.13bn−CN¥1.26bn−CN¥1.23bn−CN¥1.43bn−CN¥1.10bn−CN¥972.7m−CN¥651.2m
Free cash flowCN¥1.46bnCN¥669.0mCN¥305.4mCN¥1.28bnCN¥13.2mCN¥1.14bnCN¥648.7mCN¥809.2m−CN¥381.3m−CN¥139.3m
Dividends paid−CN¥668.5m−CN¥754.4m−CN¥756.3m−CN¥435.6m−CN¥435.6m−CN¥435.6m−CN¥435.6m−CN¥988.0m−CN¥761.5m−CN¥783.6m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥3.09bnCN¥2.82bnCN¥2.43bnCN¥3.14bnCN¥3.12bnCN¥2.82bnCN¥2.75bnCN¥2.99bn
Gross profitCN¥1.22bnCN¥1.01bnCN¥888.2mCN¥1.23bnCN¥1.09bnCN¥1.05bnCN¥557.8mCN¥1.13bn
Operating incomeCN¥470.1mCN¥390.2mCN¥270.2mCN¥394.4mCN¥435.7mCN¥310.3m−CN¥842.8mCN¥221.7m
Net incomeCN¥164.5mCN¥154.8mCN¥101.4mCN¥223.4mCN¥204.1mCN¥184.3m−CN¥751.0mCN¥138.5m
Diluted earnings per share0.080.080.050.110.100.09-0.380.07
Cash from operations———CN¥635.0mCN¥498.0mCN¥37.0m—CN¥553.0m
Capital spending−CN¥152.0m−CN¥161.0m−CN¥137.0m−CN¥160.0m−CN¥115.0m−CN¥225.0m−CN¥210.0m−CN¥167.0m
Free cash flow———CN¥475.0mCN¥383.0m−CN¥188.0m—CN¥386.0m
Total assetsCN¥29.25bnCN¥29.83bnCN¥29.03bnCN¥29.24bnCN¥29.65bnCN¥29.84bnCN¥29.45bnCN¥31.06bn
Cash and short-term investments———CN¥4.03bnCN¥4.52bnCN¥4.41bnCN¥3.94bnCN¥4.24bn
DebtCN¥3.05bnCN¥2.98bnCN¥2.28bnCN¥5.20bnCN¥6.96bnCN¥7.15bnCN¥6.50bnCN¥7.44bn
Shareholders' equityCN¥10.10bnCN¥10.40bnCN¥10.22bnCN¥9.70bnCN¥9.75bnCN¥9.53bnCN¥9.34bnCN¥10.11bn

Financial ratios

Data as of 5 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin36.9%32.9%37.8%39.8%37.6%40.5%
Operating margin13.1%1.8%8.0%12.4%10.7%11.0%
Net margin6.2%-2.6%2.6%3.3%5.4%6.0%
Return on equity7.0%-3.2%3.0%4.3%6.6%6.8%
Return on assets2.5%-1.0%1.0%1.4%2.2%2.3%
Free cash flow yield31.9%30.1%33.5%41.2%29.4%42.2%
Revenue growth-1.3%0.6%-12.4%6.4%14.3%7.8%
Earnings growth-338.5%-199.0%-30.3%-35.1%2.5%5.1%
Current ratio1.26x1.08x1.07x1.04x1.08x0.92x
Debt to equity0.22x0.70x0.85x0.79x0.97x0.95x
Equity ratio35.2%31.7%32.9%33.9%33.6%34.1%
Interest coverage4.87x0.57x2.70x3.67x2.73x2.00x
R&D as a share of sales3.0%3.2%3.6%2.9%2.7%3.0%
Buybacks as a share of market value-0.0%0.3%0.1%-0.1%-0.4%8.5%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-4.5%1.1%6.4%
Operating income-2.9%4.8%7.2%
Net income18.1%1.8%1.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin34.9%36.9%37.6%37.6%
Operating margin7.4%8.9%9.6%10.0%
Net margin1.8%2.4%3.5%4.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings13.2-29.830.523.321.416.817.118.227.931.7
Price to sales0.80.80.80.81.11.01.10.91.52.5

Dividends and splits

Per share, in the currency the company pays

Paid for 14 years. Last went ex-dividend on 16 Sept 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.200.220.220.220.220.220.220.20
  • 5-for-2 split · 27 May 2015
  • 3-for-2 split · 4 Sept 2012
  • 2-for-1 split · 15 May 2012
  • 1-to-1 reverse split · 4 Nov 2005
  • 3-for-2 split · 18 Oct 2004

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.